A genomic test led physicians to change extended endocrine therapy recommendations for 42% of people with early-stage HR-positive breast cancer.
|Podcasts|March 1, 2018
Barbells for Boobs
Author(s)Brielle Benyon
What happens when a 20-something finds a cancerous lump in her breast and is told to come back for a mammogram at the age of 40? For one group of CrossFit fanatics, it meant the launch of a nonprofit to raise money and spread awareness about breast cancer.
Advertisement
What happens when a 20-something finds a cancerous lump in her breast and is told to come back for a mammogram at the age of 40? For one group of CrossFit fanatics, it meant the launch of a nonprofit to raise money and spread awareness about breast cancer.
Read more:
Advertisement
Related to this article
These seven breast cancer clinical trials are recruiting patients now, spanning early-stage, HR-positive, HER2-positive and triple-negative disease.
Two sisters discover they share a BRCA2 mutation, but choose different paths to manage their breast cancer risk and navigate life as previvors.
A breast cancer survivor reflects on the complicated meaning of pink, remembering what cancer took, those still fighting and the people behind the ribbon.
Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.
A cancer survivor shares what to say, what not to say and how listening can help support someone through cancer treatment and beyond.
The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.
FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
Advertisement
Advertisement
Trending on CURE
1
Could a Genomic Test Spare You Extra Years of Hormone Therapy?
2
My Sister and I Share a BRCA2 Mutation. We Didn’t Make the Same Choices
3
I’m Jealous of the World — and Grateful I Got to Be Part of It
4
Three August Blood Cancer Approvals and What They Mean for Care
5